Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?

Muscle and Nerve

Volumn 49, Issue 4, 2014, Pages 483-486

  Sanders, Donald B ^a   Burns, Ted M ^b   Cutter, Gary R ^c   Massey, Janice M ^a   Juel, Vern C ^a   Hobson Webb, Lisa ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Acetylcholine receptor antibody; Clinical trials; MG composite; Myasthenia gravis; Outcome measures; QMG score

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE SEVERITY; GENERAL CONDITION IMPROVEMENT; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; PREDICTIVE VALUE; PRIORITY JOURNAL; THYMECTOMY;

ACETYLCHOLINE RECEPTOR ANTIBODY; CLINICAL TRIALS; MG COMPOSITE; MYASTHENIA GRAVIS; OUTCOME MEASURES; QMG SCORE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; DATABASES, FACTUAL; HUMANS; MYASTHENIA GRAVIS; PROSPECTIVE STUDIES; RECEPTORS, CHOLINERGIC; REGISTRIES;

EID: 84896109203     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23944     Document Type: Article

References (18)

1. Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403.
2. Tindall RSA. Humoral immunity in myasthenia gravis: effect of steroids and thymectomy. Neurology 1980;30:554-557.
3. Seybold ME, Lindstrom JM. Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis. Ann N Y Acad Sci 1981;377:292-306.
4. Olanow CW, Wechsler AS, Roses AD. A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann Surg 1982;196:113-121.
5. Oosterhuis HJGH, Limburg PC, Hummel-Tappel E, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 1983;58:371-385.
6. Vincent A, Newsom-Davis J, Newton P, Beck N. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 1983;33:1276-1282.
7. Oosterhuis HJGH, Limburg PC, Hummel-Tappel E, Van den Burg W, The TH. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy. J Neurol Sci 1985;69:335-343.
8. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.
9. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769-772.
10. Muppidi S, Wolfe GI, Conaway M, Burns TM, MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve 2011;44:727-731.
11. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487-1489.
12. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci 2003;998:440-444.
13. Burns TM, Conaway M, Cutter GR, Sanders DB, Muscle Study Group. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. Muscle Nerve 2008;38:1553-1562.
14. Kraemer HC, Morgan GA, Leech NL, Gliner JA, Harmon RJ. Measures of clinical significance. J Am Acad Child Adolesc Psychiatry 2003;42:1524-1529.
15. Sanders DB. The Duke MG clinic registry - a disease-specific database program. Ann N Y Acad Sci 2008;1132:381-382.
16. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
17. Burns TM, Conaway M, Sanders DB, MG Composite and MG-QOL15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis patient care. Neurology 2010;74:1434-1440.
18. Meriggioli MN, Sanders DB. Muscle autoantobodies in myasthenia gravis: beyond diagnosis? Exp Rev Clin Immunol 2012;8:427-438.